REG - Creo Medical Group - Proposed Sale of 49% Interest in Creo Medical SL

Creo MedicalAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260522:nRSV3600Fa&default-theme=true

RNS Number : 3600F  Creo Medical Group PLC  22 May 2026

THIS ANNOUNCEMENT WAS DEEMED BY THE COMPANY TO CONTAIN INSIDE INFORMATION AS
STIPULATED UNDER THE MARKET ABUSE REGULATIONS (EU) NO. 596/2014 AS THEY FORM
PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018.
WITH THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INFORMATION IS NOW CONSIDERED
TO BE IN THE PUBLIC DOMAIN.

 

 

Creo Medical Group plc

("Creo", the "Company" or the "Group")

 

Proposed Sale of 49% Interest in Creo Medical SL

 

Creo Medical Group plc (the "Company" or "Creo") announces that it has entered
into a non-binding agreement ("LOI") with a company (the "Purchaser") owned by
Luis Collantes, the CEO of Creo Medical S.L., regarding the potential sale and
purchase of the Company's entire 49% shareholding in Creo Medical S.L. ("Creo
Medical Europe" or "CME") (the "Proposed Transaction").

 

The LOI sets out the principal terms on which the Purchaser would acquire
Creo's remaining minority interest in CME, either directly or through a newly
incorporated acquisition vehicle. The Proposed Transaction is based on an
indicative enterprise value for CME in line with its carrying value as at 31
December 2025, subject to customary closing adjustments and on a cash-free,
debt-free basis. Consideration is expected to be satisfied in cash in full at
completion.

 

The Proposed Transaction remains subject to, inter alia, shareholder
pre-emption processes being undertaken, satisfactory completion of due
diligence by the Purchaser, agreement of definitive transaction documentation
between the parties and receipt of final financing approvals. The parties are
targeting completion within three months. There can be no certainty that the
Proposed Transaction will progress to definitive transaction documentation and
complete, nor as to the final terms of the Proposed Transaction.

 

The Proposed Transaction would enable the Company to realise value from its
minority investment and further strengthen its balance sheet to allow the
Company to continue to deliver on its accelerating growth strategy, reach
profitability and achieve sustainable cash flow generation. Creo will maintain
its strong relationship with CME, with CME to continue to act as the Company's
distributor in key European jurisdictions for its advanced energy products.
 On completion, the Company will not participate in any future profits or
dividends from CME.

 

A further announcement in respect of the Proposed Transaction will be made in
due course.

 

Craig Gulliford, Chief Executive Officer of Creo Medical, said:

"This proposed transaction represents an opportunity to crystallise value from
our minority interest in CME at an attractive valuation. It supports our
strategic priority of simplifying the Group and strengthening the balance
sheet, while enabling continued investment in our product range, commercial
expansion and other commercialisation opportunities with our technology
platform."

 

For further information please contact:

 

 Creo Medical Group plc                                                  www.creomedical.com
                                                                         (https://protect.checkpoint.com/v2/r02/___https:/www.creomedical.com___.YXAxZTpzaG9yZWNhcDpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDozYjJjMmUxYTg2MzVlYWZhNGZjNWY4ZWRkMDA5MjczZTo3OmJmNmY6ZTFlNWNmMTk2ZGNkNWIwNGM0N2Q0NGZlMWExODc2NTQ0NzQzY2Q4M2M4ZTdlODI2ZTBkYmIzYzZkOTcyNjg0MDpwOlQ6Tg)
 Richard Craven, Company Secretary                                       Via Walbrook PR

 Deutsche Numis (Nominated Adviser and Joint Broker)                     +44 (0)20 7545 8000

 Duncan Monteith / Sher Shah

 Shore Capital (Joint Broker)                                            +44 (0)20 7408 4090

 Daniel Bush / Lucy Bowden

 Walbrook PR Ltd                Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com (mailto:creo@walbrookpr.com)
 Paul McManus / Alice Woodings  Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

About Creo Medical

Creo is a medical device company focused on the development and
commercialisation of minimally invasive electrosurgical devices, bringing
advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development
and commercialisation of a suite of electrosurgical medical devices, each
enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA
powered by Kamaptive full-spectrum adaptive technology to optimise surgical
capability and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection, coagulation,
and ablation of tissue. Kamaptive technology provides clinicians with
increased flexibility, precision and controlled surgical solutions. CROMA
currently delivers bipolar radiofrequency ("RF") energy for precise localised
cutting and focused high frequency microwave ("MW") energy for controlled
coagulation and ablation via a single accessory port. This technology,
combined with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and controlled clinical
solutions. The Directors believe the Company's technology can impact the
landscape of surgery and endoscopy by providing a safer, less invasive and
more cost-efficient option for procedures.

 

For more information, please refer to the website www.creomedical.com
(https://protect.checkpoint.com/v2/r02/___http:/www.creomedical.com/___.YXAxZTpzaG9yZWNhcDpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDoxNTZlNmNmODM3NDc3ODdmYzAwOTJlYzk4MzA1YzViZTo3OmE1MDA6MDcwYzMwMDUxYjg3OGI5MDFiMDBiYWRhYmQ3NTM1YzZlZTNjZTgzOGY4YjY4MTE4OGY0NDVlMzg0YjVmNTFkZTpwOkY6Tg)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCDGGDUSUDDGLB



            Copyright 2019 Regulatory News Service, all rights reserved